secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-126734
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics Q3 net loss $6.1M; FDA approved ORLYNVAH in October 2024
----------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments totaled $14.5M at Sept. 30, 2024.
- FDA approved ORLYNVAH for uUTI on Oct. 25, 2024; 10 years of GAIN Act exclusivity.
- Net loss Q3 2024 was $6.1M vs $3.9M in Q3 2023; non-GAAP net loss $4.8M vs $15.7M.
- R&D expenses fell to $3.1M from $14.9M due to completion of REASSURE trial enrollment.
- Company seeking strategic partners for ORLYNVAH; cash expected to fund into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024126734/0000950170-24-126734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024126734/itrm-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer